NervGen Pharma (NASDAQ:NGEN) Raised to Hold at Wall Street Zen

NervGen Pharma (NASDAQ:NGEN) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Friday.

A number of other equities research analysts also recently weighed in on the company. HC Wainwright upgraded NervGen Pharma to a “strong-buy” rating in a report on Tuesday, April 28th. Weiss Ratings initiated coverage on NervGen Pharma in a research note on Friday, April 24th. They set a “sell (d-)” rating for the company. Stifel Nicolaus upgraded NervGen Pharma to a “strong-buy” rating in a research note on Thursday, April 23rd. Finally, Zacks Research upgraded NervGen Pharma to a “hold” rating in a research note on Wednesday, April 29th. Two research analysts have rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $18.00.

NervGen Pharma Stock Up 0.5%

Shares of NASDAQ NGEN opened at $2.08 on Friday. NervGen Pharma has a twelve month low of $1.50 and a twelve month high of $6.30.

NervGen Pharma (NASDAQ:NGEN) last issued its quarterly earnings results on Friday, May 15th. The company reported $999.00 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $999.07.

About NervGen Pharma

NervGen Pharma Corp. is a clinical-stage biotechnology company focused on developing therapies to promote nerve repair and restore neurological function following injury or disease. The company advances regenerative approaches intended to address damage in the central and peripheral nervous systems, pursuing programs that aim to translate preclinical repair concepts into human treatments.

The company’s lead investigational candidate is NVG-291, which is being evaluated in clinical studies for indications that include spinal cord injury, neuropathic conditions and neurodegenerative disease settings.